Nov 20, 2023
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
Nov 13, 2023
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
Nov 10, 2023
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Nov 07, 2023
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
Nov 03, 2023
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
Nov 02, 2023
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
Oct 26, 2023
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
Oct 25, 2023
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
Oct 23, 2023
Aligos Therapeutics Announces $92 Million Private Placement Financing
Oct 03, 2023
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
Displaying 1 - 10 of 29